A promising vaccine candidate for tuberculosis is getting a new lease of life after two major funders have decided to pour US$550 million into its final phase of clinical trials. If successful, it would be the first new tuberculosis vaccine on the market in more than a century.
Read more here: https://www.nature.com/articles/d41586-023-02171-x
